Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001607062-19-000409
Filing Date
2019-10-25
Accepted
2019-10-24 18:54:40
Documents
51
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q zander093019form10q.htm 10-Q 487751
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 8510
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 8387
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6232
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 6401
  Complete submission text file 0001607062-19-000409.txt   2267545

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE zander-20190930.xml EX-101.INS 291762
7 XBRL SCHEMA FILE zander-20190930.xsd EX-101.SCH 32017
8 XBRL CALCULATION FILE zander-20190930_cal.xml EX-101.CAL 45527
9 XBRL DEFINITION FILE zander-20190930_def.xml EX-101.DEF 113271
10 XBRL LABEL FILE zander-20190930_lab.xml EX-101.LAB 171845
11 XBRL PRESENTATION FILE zander-20190930_pre.xml EX-101.PRE 168787
Mailing Address 4700 SPRING ST LA MESA CA 91942-0274
Business Address 4700 SPRING ST LA MESA CA 91942-0274 6192279192
Zander Therapeutics, Inc (Filer) CIK: 0001718644 (see all company filings)

EIN.: 474321638 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 333-220790 | Film No.: 191166826
SIC: 2834 Pharmaceutical Preparations